Back to Peptides

Chonluten

Moderate Research

EDG Tripeptide | Bronchial/Lung Bioregulator

Dose 10-20 mg daily
Frequency Once daily for 10-20 consecutive days
Cycle 10-20 days per cycle
Storage Capsules: room temperature; Injectable lyophilized: 2-8°C; Reconstituted: 2-8°C refrigerated

Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.

Mechanism of Action

Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.

Key Benefits

  • Normalizes respiratory system function
  • Regulates protein synthesis in lung tissue
  • Inhibits inflammatory TNF production
  • Restores lung alveolar tissues
  • Maintains bronchial mucous membranes
  • Supports antioxidant gene expression
  • May slow cell aging (geroprotective)
  • Modulates mucosal function
Molecular Weight
319 Da
Chain Length
3 amino acids
Type
Tripeptide bioregulator
Amino Acid Sequence
One-letter: EDG
H₂N
E 1
O ‖ C
N
D 2
O ‖ C
N
H
G 3
COOH
Glu
1

Glutamic Acid

Position 1

Asp
2

Aspartic Acid

Position 2

Gly
3

Glycine

Position 3

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Respiratory Support

  • Bronchial Function

    Normalizes respiratory system function through gene expression regulation.

  • Lung Tissue Health

    Restores and maintains lung alveolar tissues and bronchial mucous membranes.

  • COPD Support

    May modulate mucosal function in chronic obstructive pulmonary disease.

Anti-Inflammatory

  • TNF Modulation

    Inhibits TNF production in monocytes, reducing inflammatory responses.

  • Oxidative Stress

    Supports SOD and antioxidant gene expression.

Anti-Aging

  • Geroprotection

    Researched as potential agent that may slow cell aging.

  • Gene Expression Regulation

    Modulates c-Fos and proliferative gene activity.

Available in capsule form for oral administration. As a tripeptide, Chonluten has favorable permeability across cellular compartments. Typical protocol involves 10-20 day cycles.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysOral capsules
Maintenance10 mg2-3 cycles yearlyOral capsules
Bronchogen

Related respiratory bioregulators; complementary mechanisms.

synergistic
Epitalon

Often combined in comprehensive anti-aging Khavinson protocols.

synergistic
Crystagen

Both have immune-modulating properties; different tissue targets.

compatible
BPC-157

Both support mucosal health through different mechanisms.

compatible
During cycle

Gene expression modulation and anti-inflammatory effects begin

Post-cycle

Effects persist due to epigenetic changes

Weeks-Months

Respiratory function improvements

Long-term

Cumulative benefits with periodic cycles

Common Side Effects

  • Generally well-tolerated
  • Minimal side effects reported

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual respiratory symptoms

Contraindications

  • Active respiratory emergencies (seek medical care)
  • Known hypersensitivity
  • Pregnancy or breastfeeding

Good Signs

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling

Warning Signs

  • Unknown source or purity

Bad Signs

  • Discoloration
  • Unusual odor
  • Damaged packaging
  • Peptides Regulating Proliferative Activity and Inflammatory Pathways in THP-1 Cells
    PMC/NCBI (2022)

    Chonluten tripeptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS.

  • Chonluten and Gene Expression Regulation
    Advances in Gerontology (2018)

    Chonluten regulates c-Fos, HSP70, SOD, COX-2, and TNF-alpha gene expression.

  • Bronchial Bioregulator Peptides
    Bulletin of Experimental Biology and Medicine (2016)

    Short peptides derived from bronchial tissue regulate protein synthesis in lung cells.

  • Khavinson Peptide Bioregulators
    Advances in Gerontology (2020)

    Comprehensive review of bioregulator peptides including Chonluten and their mechanisms.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.